CFTR and cystic fibrosis: The advent of novel CFTR modulators with resultant drug–drug interactions alongside the need for shielding in a COVID-19 pandemic has only heightened these issues and make integration of robust antifungal stewardship programmes in CF fungal disease a priority.48